Alexion and Moderna have an exclusive strategic agreement for the discovery and development of messenger RNA Therapeutics™ for rare diseases.
Moderna announces a landmark publication describing the first-ever protein production through messenger RNA therapeutics™.
Moderna and AstraZeneca have a strategic option agreement to develop up to forty messenger RNA Therapeutics™ for the treatment of serious cardiometabolic diseases and cancer.
We are delivering the next wave of innovation to treat serious illness.
We’ve assembled a team of scientists and drug hunters, executives and visionaries. Our experience is matched only by our passion.
watch our video
March 6, 2014
Moderna appoints biotechnology investment banking veteran Lorence Kim as Chief Financial Officer | Read more
February 19, 2014
Massachusetts Life Sciences Center awards tax incentive to Moderna Therapeutics | Read more
January 14, 2014
Moderna spins-out Onkaido Therapeutics to focus on the development of messenger RNA Therapeutics™ in oncology | Read more